Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
Prof Ulrike Leiter-Stoppke speaks with ecancer at the EADO 2018 congress about the Central Malignant Melanoma Registry in Germany.
Prof Leiter-Stoppke explains that the registry collects clinical and epidemiological data so far from 138,000 patients.
She also explains that an online system was set up in 2013 in order to collect a wider variety of data including therapeutic and metastatic data.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
OncoAlert Round Up for September 15-21, 2023
The 5-year long-term outcomes of radiation technique for locally advanced NSCLC
NSIA and Nigeria to improve treatment for Nigerians through the building of new cancer centres
Choosing Wisely in radiology Tanzania
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer
TARGIT-E: Intraoperative Radiotherapy (IORT) in elderly patients with small breast cancer
The use of IORT at Universitätsmedizin Mannheim hospital
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours